Laryngeal Squamous Cell Carcinoma Cell Models for Research

Laryngeal squamous cell carcinoma (LSCC) accounts for approximately 2% of all cancers worldwide, with an estimated 184,000 new cases and 95,000 deaths annually (WHO GLOBOCAN 2020). The highest incidence rates are observed in Southern and Eastern Europe, South America, and South Asia, largely driven by tobacco smoking and alcohol consumption. Human papillomavirus (HPV) infection is less common in laryngeal cancer compared to oropharyngeal cancer, but HPV-positive cases exhibit distinct molecular profiles and better prognosis. The 5-year survival rate for localized LSCC is around 75%, but it drops to 40% for regional spread and 20% for distant metastasis (NCI SEER). Recurrence rates remain high (30-50%) despite advances in surgery and chemoradiotherapy, underscoring the need for targeted therapies and predictive biomarkers.

LSCC is an ideal model for studying epithelial carcinogenesis due to its well-defined risk factors, stepwise progression from hyperplasia to dysplasia to carcinoma, and frequent genetic alterations in TP53, CDKN2A, and PIK3CA. The availability of public datasets (TCGA, COSMIC) and established cell lines (e.g., UMSCC, SCC-25) enables mechanistic studies. Key open questions include the role of tumor heterogeneity, immune evasion, and resistance to EGFR inhibitors. Gene-edited cell models allow researchers to dissect the functional impact of specific mutations in a controlled isogenic background, accelerating target validation and drug development.

LSCC arises from accumulation of genetic and epigenetic alterations in key pathways. The main carcinogenic pathways include:

• • TP53 pathway: Loss of p53 function leads to genomic instability, impaired apoptosis, and cell cycle dysregulation. TP53 mutations are early events in LSCC.
• • RB1 pathway: CDKN2A loss (p16 inactivation) results in uncontrolled cell proliferation via CDK4/6-cyclin D1 activation.
• • EGFR signaling: Overexpression or activating mutations of EGFR drive proliferation, survival, and metastasis via RAS/RAF/MEK/ERK and PI3K/AKT pathways.
• • PI3K/AKT/mTOR pathway: PIK3CA mutations or PTEN loss activate survival signals and resistance to apoptosis.
• • Wnt/β-catenin pathway: Aberrant activation promotes epithelial-mesenchymal transition (EMT) and invasion.

Data from TCGA and COSMIC reveal recurrent somatic mutations in LSCC. The following table summarizes key genes, their mutation frequencies, types, and functional effects:

LSCC is characterized by aberrant activation of several signaling networks that interact to promote tumor progression. Key networks include:

• • MAPK/ERK pathway: Activated by EGFR, HRAS, or BRAF mutations; promotes proliferation and survival.
• • PI3K/AKT pathway: Activated by PIK3CA mutations or PTEN loss; regulates cell growth, metabolism, and apoptosis resistance.
• • Wnt/β-catenin pathway: FAT1 loss or CTNNB1 mutations lead to β-catenin stabilization and transcription of target genes (MYC, CCND1).
• • NF-κB pathway: Chronic inflammation and TNF-α signaling activate NF-κB, promoting survival and invasion.
• • JAK/STAT pathway: Cytokine signaling (IL-6, IFN-γ) activates STAT3, contributing to immune evasion and stemness.

These networks provide multiple targets for therapeutic intervention, and gene-edited models can be used to study pathway crosstalk and resistance mechanisms.

Several LSCC cell lines are widely used in research. The table below lists common cell lines, their origins, and key mutations:

Organoid cultures derived from patient tumors preserve the genetic heterogeneity and 3D architecture of the original tumor, making them valuable for drug testing and personalized medicine. However, gene-edited cell lines offer a more controlled system for mechanistic studies.

Animal models are essential for studying LSCC in vivo. Common models include:

• • Patient-derived xenografts (PDX): Tumor fragments implanted into immunodeficient mice; retain patient-specific mutations and histology.
• • Genetically engineered mouse models (GEMM): Conditional knockout of TP53 and/or PTEN in the laryngeal epithelium leads to tumor formation.
• • Chemical-induced models: Treatment with 4-nitroquinoline-1-oxide (4-NQO) in drinking water induces oral and laryngeal squamous cell carcinoma in mice.
• • Syngeneic models: Mouse cell lines (e.g., SCC7) implanted into immunocompetent mice to study immune interactions.

These models are useful for validating drug efficacy and studying tumor microenvironment, but they are time-consuming and costly. Gene-edited cell lines provide a faster, more reproducible alternative for initial screening.

CRISPR-based gene editing enables the generation of isogenic cell lines with precise genetic modifications, such as knockouts, knock-ins, and point mutations. For LSCC, common gene-edited models include:

• • TP53 knockout: Loss of p53 function in a wild-type background to study genomic instability and drug resistance.
• • PIK3CA knock-in (H1047R): Constitutive activation of PI3K/AKT pathway to test PI3K inhibitors.
• • CDKN2A knockout: Loss of p16 to model cell cycle dysregulation.
• • EGFR overexpression: Amplification of EGFR to study receptor signaling and sensitivity to EGFR inhibitors.

These models are commercially available from various sources, and sequence-verified clones ensure reproducibility. They are essential for functional genomics, drug screening, and target validation, as they allow direct comparison between mutant and wild-type cells in an identical genetic background.

Gene-edited cell lines are powerful tools for functional genomics. By knocking out or knocking in specific genes, researchers can determine their role in tumorigenesis, metastasis, and drug response. For example:

• • TP53 knockout in LSCC cells leads to increased proliferation and resistance to apoptosis, confirming its tumor suppressor role.
• • PIK3CA knock-in (H1047R) enhances cell migration and invasion, demonstrating its oncogenic function.
• • NOTCH1 knockout results in loss of differentiation and increased stemness, highlighting its role in maintaining epithelial phenotype.

These models enable high-throughput screening to identify genetic dependencies and synthetic lethal interactions.

Isogenic pairs (wild-type vs. gene-edited) are ideal for drug screening because they eliminate confounding genetic variability. Applications include:

• • EGFR inhibitor sensitivity: Cells with EGFR amplification are more sensitive to erlotinib or cetuximab; TP53 knockout may confer resistance.
• • PI3K inhibitor testing: PIK3CA-mutant cells show increased sensitivity to PI3K/mTOR inhibitors compared to wild-type.
• • Resistance modeling: Chronic exposure to drugs can select for resistant clones; gene-edited cells can be used to identify resistance mutations (e.g., secondary EGFR mutations).

These models accelerate the development of targeted therapies and combination strategies.

CRISPR-based screens using gene-edited cell lines can identify novel biomarkers and therapeutic targets. For example:

• • Synthetic lethality screens: Knocking out genes in TP53-deficient cells to identify vulnerabilities that are not present in TP53-wild-type cells.
• • CRISPR activation/inhibition screens: Overexpressing or silencing genes to identify those that confer resistance to chemotherapy or immunotherapy.
• • Proteomic and transcriptomic profiling: Gene-edited cells can be used to identify downstream effectors of specific mutations, leading to candidate biomarkers for patient stratification.

These approaches are critical for precision medicine in LSCC.

The following databases provide valuable genomic, transcriptomic, and functional data for LSCC research: